AstraZeneca Non-GAAP EPS of $1.89 beats by $0.76, revenue of $11.39B beats by $430M
AstraZeneca press release (NASDAQ:AZN): Q1 Non-GAAP EPS of $1.89  beats by $0.76.
Revenue of $11.39B (+55.6% Y/Y)  beats by $430M.
Tagrisso revenue of $1.30B (+14 Y/Y)
Lynparza revenue of $792M (+46% Y/Y).
Imfinzi revenue of $599M (+8 Y/Y).
Enhertu revenue of $86M.
Total Oncology revenue increased by 21% (25% at CER) in Q1 2022 to $3,644M and represented 32% of overall Total Revenue (Q1 2021: 41%).
EBITDA of $2,187M in the quarter (Q1 2021: $2,692M).
The Company reiterates FY 2022 guidance at CER: Total Revenue is expected to increase by a high teens percentage (consensus of $43.72B) Core EPS is expected to increase by a mid-to-high twenties percentage (consensus of $4.00).
A Core Tax Rate between 18-22%.
Total Revenue from COVID-19 medicines is anticipated to decline by a low-to-mid twenties percentage, with an expected decline in sales of Vaxzevria being partially offset by growth in Evusheld sales.
The Gross Margin from the COVID19 medicines is expected to be lower than the Company average â Core Operating Expenses are expected to increase by a low-to-mid teens percentage, driven in substantial part by the full year integration of Alexion expenses.